Hospital
Scheurer Hospital
Scheurer Hospital was paid $3.15M by Medicaid between Jan 2018 and Dec 2024, across 100 billing codes. Its largest line is 99284, emergency room visit (serious) — 31% of everything it billed.
33Billing provider infoSCHEURER HOSPITAL
PIGEON, MI 48755
PIGEON, MI 48755
33aNPI1437102993assigned 05/18/2006
33bProvider typeCritical Access Hospital
28Total paid$3.15M
24GClaims108,079
24DCodes billed100
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Michigan
Rank by total paid#20 of 31
Median peer was paid$6.03M
This provider vs. median0.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 16,580 | $324K | |
| 2019 | 14,951 | $282K | |
| 2020 | 12,512 | $333K | |
| 2021 | 16,668 | $533K | |
| 2022 | 16,759 | $547K | |
| 2023 | 16,966 | $596K | |
| 2024incomplete | 13,643 | $540K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 31% | 3,718 | 3,454 | $977K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 25% | 4,863 | 4,604 | $777K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.8% | 687 | 649 | $310K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 5.6% | 6,404 | 1,504 | $176K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.3% | 1,700 | 1,646 | $103K |
| 71046 | Radiologic examination, chest; 2 views | 2.7% | 1,815 | 1,708 | $85K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2.6% | 844 | 818 | $83K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.3% | 1,010 | 973 | $72K |
| 80061 | Lipid panel | 1.5% | 4,111 | 4,091 | $47K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.4% | 355 | 317 | $44K |
| 80053 | Comprehensive metabolic panel | 1.3% | 9,193 | 8,250 | $41K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.1% | 3,662 | 3,570 | $36K |
88 more codes
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 995 | $28K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,525 | $28K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 441 | $27K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 10,410 | $27K |
| 36415 | Collection of venous blood by venipuncture | <1% | 11,768 | $23K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 92 | $22K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,301 | $21K |
| 97161 | <1% | 274 | $18K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 163 | $17K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,823 | $17K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 659 | $15K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,035 | $13K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,893 | $12K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,122 | $11K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 249 | $10K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 147 | $9K |
| 97014 | <1% | 1,228 | $9K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 41 | $7K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 183 | $7K |
| 84439 | <1% | 1,041 | $6K | |
| 87081 | <1% | 1,482 | $6K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 375 | $6K |
| 85610 | <1% | 2,489 | $5K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,480 | $5K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,029 | $4K |
| 82607 | <1% | 434 | $4K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 13 | $4K |
| 85027 | <1% | 943 | $3K | |
| 73630 | <1% | 131 | $3K | |
| 83735 | <1% | 2,180 | $3K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 53 | $3K |
| 87077 | <1% | 513 | $2K | |
| 73564 | <1% | 56 | $2K | |
| 87186 | <1% | 435 | $2K | |
| 82043 | <1% | 454 | $2K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 80 | $2K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 80 | $2K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 47 | $2K |
| 81001 | <1% | 2,974 | $2K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 57 | $1K |
| 83690 | <1% | 1,606 | $1K | |
| 87631 | <1% | 237 | $1K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 314 | $1K |
| 87088 | <1% | 482 | $1K | |
| 73610 | <1% | 68 | $998.05 | |
| 97162 | <1% | 27 | $866.21 | |
| 86140 | <1% | 628 | $801.14 | |
| 72110 | <1% | 15 | $796.06 | |
| 84450 | <1% | 846 | $752.77 | |
| 82570 | <1% | 196 | $685.63 | |
| 73130 | <1% | 25 | $678.72 | |
| 82150 | <1% | 908 | $660.54 | |
| 82728 | <1% | 67 | $599.04 | |
| 87070 | <1% | 71 | $353.08 | |
| 83540 | <1% | 75 | $315.66 | |
| 85730 | <1% | 1,170 | $268.24 | |
| 84484 | <1% | 1,005 | $258.38 | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 13 | $257.09 |
| 73030 | <1% | 13 | $255.60 | |
| 80306 | <1% | 97 | $246.18 | |
| 82550 | <1% | 913 | $192.75 | |
| 83615 | <1% | 1,712 | $154.18 | |
| 83550 | <1% | 25 | $144.98 | |
| 87807 | <1% | 30 | $134.67 | |
| 84460 | <1% | 45 | $125.99 | |
| 84703 | <1% | 205 | $83.75 | |
| 81003 | <1% | 124 | $83.12 | |
| 82977 | <1% | 672 | $77.39 | |
| 81025 | <1% | 383 | $55.77 | |
| 85652 | <1% | 26 | $30.30 | |
| 87400 | <1% | 50 | $25.98 | |
| 85651 | <1% | 12 | $22.07 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 203 | $20.26 |
| 85007 | <1% | 15 | $19.00 | |
| 85379 | <1% | 30 | $16.36 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,900 | $1.16 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 255 | $0.00 |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 0% | 118 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 27 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 47 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 13 | $0.00 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 0% | 38 | $0.00 |
| A9270 | Non-covered item or service | 0% | 770 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 232 | $0.00 |
| J3490 | Unclassified drugs | 0% | 117 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 69 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 114 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRAMSEY, ROSS (CEO & PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Scheurer Hospital | Pigeon, MI | $1.81M |
| Scheurer Hospital | Pigeon, MI | $571K |
| Scheurer Hospital | Pigeon, MI | $520K |
| Scheurer Hospital | Sebewaing, MI | $268K |
| Scheurer Hospital | Bad Axe, MI | $257K |
| Oakdale Chiropractic Clinic | Oakdale, LA | $185K |
| Scheurer Hospital | Elkton, MI | $140K |
| Scheurer Hospital | Pigeon, MI | $107K |
| Scheurer Hospital | Caseville, MI | $102K |
| Scheurer Hospital | Pigeon, MI | $0.03 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.